Shorter Radiotherapy, Fewer Toxicities in Breast Cancer?

TOPLINE: In patients with breast cancer, a 3-week moderately hypofractionated radiation therapy regimen resulted in lower rates of grade ≥ 2 adverse events (AEs) overall than conventional 5-week treatment, according to the first results from the phase 3 UNICANCER HypoG-01 trial. METHODOLOGY: While hypofractionated radiotherapy is widely accepted for treating breast cancer…